CD274 and neoplasm: Median (95% CI) DOR was 59.1 (24.5–NR) months with nivolumab plus ipilimumab versus 7.1 (3.9–31.6) months with chemotherapy in the tumor PD-L1 ≥ 1% population, 17.3 (7.2–NR) versus 3.0 (2.6–5.6) months in the tumor PD-L1 < 1% population, and 29.0 (18.0–NR) versus 5.6 (3.1–7.1) months in the combined PD-L1 ≥ 1% and < 1% population (Table 4).